JP6768012B2 - 広域スペクトル抗感染ペプチド - Google Patents

広域スペクトル抗感染ペプチド Download PDF

Info

Publication number
JP6768012B2
JP6768012B2 JP2017567056A JP2017567056A JP6768012B2 JP 6768012 B2 JP6768012 B2 JP 6768012B2 JP 2017567056 A JP2017567056 A JP 2017567056A JP 2017567056 A JP2017567056 A JP 2017567056A JP 6768012 B2 JP6768012 B2 JP 6768012B2
Authority
JP
Japan
Prior art keywords
peptide
infective
specific embodiment
virus
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017567056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531880A5 (enExample
JP2018531880A (ja
Inventor
チョ ナム‐ジョオン
チョ ナム‐ジョオン
アレクサンダー ジャックマン ジョシュア
アレクサンダー ジャックマン ジョシュア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanyang Technological University
Original Assignee
Nanyang Technological University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Technological University filed Critical Nanyang Technological University
Publication of JP2018531880A publication Critical patent/JP2018531880A/ja
Publication of JP2018531880A5 publication Critical patent/JP2018531880A5/ja
Application granted granted Critical
Publication of JP6768012B2 publication Critical patent/JP6768012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44—Guanidine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1833—Hepatitis C; Hepatitis NANB
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D189/00—Coating compositions based on proteins; Coating compositions based on derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Dermatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Materials Engineering (AREA)
JP2017567056A 2015-06-25 2016-06-24 広域スペクトル抗感染ペプチド Active JP6768012B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562184354P 2015-06-25 2015-06-25
US62/184,354 2015-06-25
PCT/SG2016/050291 WO2016209173A1 (en) 2015-06-25 2016-06-24 Broad-spectrum anti-infective peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019184326A Division JP2020040950A (ja) 2015-06-25 2019-10-07 広域スペクトル抗感染ペプチド

Publications (3)

Publication Number Publication Date
JP2018531880A JP2018531880A (ja) 2018-11-01
JP2018531880A5 JP2018531880A5 (enExample) 2019-08-08
JP6768012B2 true JP6768012B2 (ja) 2020-10-14

Family

ID=57586064

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017567056A Active JP6768012B2 (ja) 2015-06-25 2016-06-24 広域スペクトル抗感染ペプチド
JP2019184326A Pending JP2020040950A (ja) 2015-06-25 2019-10-07 広域スペクトル抗感染ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019184326A Pending JP2020040950A (ja) 2015-06-25 2019-10-07 広域スペクトル抗感染ペプチド

Country Status (12)

Country Link
US (3) US10351604B2 (enExample)
EP (1) EP3313862B9 (enExample)
JP (2) JP6768012B2 (enExample)
KR (1) KR20180037185A (enExample)
CN (1) CN107922461A (enExample)
AU (1) AU2016281477A1 (enExample)
BR (1) BR112017028190A2 (enExample)
CA (1) CA2989399A1 (enExample)
HK (1) HK1248248A1 (enExample)
MX (1) MX2017016227A (enExample)
SG (1) SG10201912866RA (enExample)
WO (1) WO2016209173A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028190A2 (pt) 2015-06-25 2018-09-04 Univ Nanyang Tech Peptídeo, peptídeo peguilado, composição, composição farmacêutica, frasco, solução de desinfecção, método para inibição de crescimento, replicação ou infectividade de um micro- organismo, método para inibição de crescimento bacteriano, método para inibição de replicação viral em uma célula, método para tratamento de uma infecção de micro-organismo em um sujeito e prevenção de uma doença em um sujeito causada por ou associada a uma infecção de micro- organismo, método para inibição de crescimento bacteriano em um sujeito, método para tratamento de uma infecção bacteriana em um sujeito e tratamento de uma doença causada por ou associada a uma infecção bacteriana, método para prevenção de uma doença causada por ou associada a uma infecção bacteriana em um sujeito, método para inibição de replicação viral em um sujeito, método para tratamento de uma infecção viral em um sujeito e tratamento de uma doença causada por ou associada a uma infecção viral em um sujeito, método para prevenção de uma doença causada por ou associada a uma infecção viral em um sujeito, método para desinfecção de um objeto inanimado ou material biológico e superfície inanimada ou superfície biológica
WO2020047203A2 (en) * 2018-08-30 2020-03-05 Osel, Inc. Bacteriocins to improve vaginal colonization of hydrogen peroxide producing lactobacillus for female reproductive health
US20230256049A1 (en) * 2020-07-24 2023-08-17 Oak Crest Institute Of Science Materials and methods for the prevention and treatment of viral respiratory diseases
WO2022220749A1 (en) * 2021-04-13 2022-10-20 Nanyang Technological University Anti-viral peptide compositions and methods to improve biological activity thereof
US20240197814A1 (en) * 2021-04-27 2024-06-20 Oak Crest Institute Of Science Materials and methods for the prevention and treatment of viral diseases
CN117756904B (zh) * 2023-12-22 2024-05-24 潍坊医学院 一种订书肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002259130A1 (en) * 2001-05-03 2002-11-18 Eli Lilly And Company Agents for treatment of hcv and methods of use
EP1357127A1 (de) * 2002-04-10 2003-10-29 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
EP1537418A2 (en) * 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
WO2004028563A1 (en) * 2002-09-27 2004-04-08 Genexine Inc. A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus
NZ551319A (en) * 2004-05-17 2010-07-30 Novartis Vaccines & Diagnostic Truncated Hepatitis C virus NS5 domain and fusion proteins comprising same
US20070073039A1 (en) 2005-09-29 2007-03-29 Chisari Francis V Peptides that inhibit viral infections
TW200837075A (en) * 2007-01-10 2008-09-16 Scripps Research Inst Antiviral peptides
EP2508531B1 (en) * 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
WO2009014615A2 (en) * 2007-07-19 2009-01-29 The Board Of Trustees Of The Leland Stanford Junior University Amphipathic alpha-helical peptide compositions as antiviral agents
JP2011508785A (ja) 2008-01-03 2011-03-17 マサチューセッツ インスティテュート オブ テクノロジー デコイインフルエンザ処置
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
RU2447899C2 (ru) 2010-05-27 2012-04-20 Михаил Валентинович Филатов Композиция для лечения гепатита с и способ лечения гепатита с
EP2763532B1 (en) * 2011-10-05 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Pi-kinase inhibitors with broad spectrum anti-infective activity
BR112017028190A2 (pt) 2015-06-25 2018-09-04 Univ Nanyang Tech Peptídeo, peptídeo peguilado, composição, composição farmacêutica, frasco, solução de desinfecção, método para inibição de crescimento, replicação ou infectividade de um micro- organismo, método para inibição de crescimento bacteriano, método para inibição de replicação viral em uma célula, método para tratamento de uma infecção de micro-organismo em um sujeito e prevenção de uma doença em um sujeito causada por ou associada a uma infecção de micro- organismo, método para inibição de crescimento bacteriano em um sujeito, método para tratamento de uma infecção bacteriana em um sujeito e tratamento de uma doença causada por ou associada a uma infecção bacteriana, método para prevenção de uma doença causada por ou associada a uma infecção bacteriana em um sujeito, método para inibição de replicação viral em um sujeito, método para tratamento de uma infecção viral em um sujeito e tratamento de uma doença causada por ou associada a uma infecção viral em um sujeito, método para prevenção de uma doença causada por ou associada a uma infecção viral em um sujeito, método para desinfecção de um objeto inanimado ou material biológico e superfície inanimada ou superfície biológica

Also Published As

Publication number Publication date
US11866460B2 (en) 2024-01-09
JP2020040950A (ja) 2020-03-19
CN107922461A (zh) 2018-04-17
SG10201912866RA (en) 2020-02-27
US20180186837A1 (en) 2018-07-05
AU2016281477A1 (en) 2018-01-04
KR20180037185A (ko) 2018-04-11
US20200087349A1 (en) 2020-03-19
BR112017028190A2 (pt) 2018-09-04
EP3313862B1 (en) 2023-06-07
EP3313862A4 (en) 2019-01-23
HK1248248A1 (zh) 2018-10-12
US20220402972A1 (en) 2022-12-22
EP3313862A1 (en) 2018-05-02
CA2989399A1 (en) 2016-12-29
JP2018531880A (ja) 2018-11-01
US10351604B2 (en) 2019-07-16
WO2016209173A1 (en) 2016-12-29
MX2017016227A (es) 2019-03-28
EP3313862B9 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
US11866460B2 (en) Broad-spectrum anti-infective peptides
JP7267251B2 (ja) 抗菌組成物及び医薬組成物
Huo et al. Overcoming planktonic and intracellular Staphylococcus aureus-associated infection with a cell-penetrating peptide-conjugated antimicrobial peptide
US20230391839A1 (en) Bioactive peptides derived from snakes
JP6769871B2 (ja) Ｅ．ｃｏｌｉ感染のファージを用いての治療
ES2926129T3 (es) Terapia con fagos
ES2857199T3 (es) Terapia con fagos de infecciones de Pseudomonas
JP6736476B6 (ja) 局所性および全身性細菌感染症の治療
CN107022001A (zh) 一种分离的母乳内源性抗菌多肽及其应用
JP5612314B2 (ja) ウィルス・細菌を破壊しその感染増殖を抑制する薬剤および方法
CN117138024B (zh) 一种万古霉素-抗菌肽偶合物及其应用
JP2014512353A (ja) 抗ウイルス組成物
WO2016146037A1 (zh) 用于抑制/瓦解生物被膜的抑制剂及其应用
JP4441180B2 (ja) ウイルス由来抗微生物ペプチド
JPH05505390A (ja) レトロウィルス類のウィルスに対する活性剤、該活性剤を含有する組成物、及びそれらの使用
JP2005318829A (ja) 抗菌性ペプチド、該抗菌性ペプチドをコードするポリヌクレオチド、並びに該抗菌性ペプチドを含有する抗菌剤、抗菌性医薬、点眼薬及び眼感染症疾患検査薬
EP4720263A1 (en) Phage therapy utilizing a unique cocktail of pseudomonas aeruginosa phages
CA2966944C (en) Pseudomonas aeruginosa bacteriophage therapy
JP2006045067A (ja) 抗菌ペプチド及びその利用
WO2009040543A2 (en) Bioactive peptide
CN1589873A (zh) 一种治疗鼻炎的药物喷剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190620

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200408

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200610

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200707

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200918

R150 Certificate of patent or registration of utility model

Ref document number: 6768012

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250